Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
Diagnosis of invasive breast cancer in the breast and axilla was histopathologically confirmed and defined according to WHO classification 9 . ER, PR, and HER2 statuses were evaluated by immunohistochemistry or fluorescence in situ hybridization before NAC administration. Tumor subtypes were defined as follows [12]: luminal A; ER(+) or PR(+), HER2-neu (–), Ki67 <20%; luminal B, ER(+) or PR(+), and/or HER2-neu (+), Ki67 ≥20%; non-luminal HER2-neu(+), ER(–) PR(–) HER2-neu (+); and triple-negative, ER(–) PR (–) HER2-neu (–).
Copyright and License information: ©2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
